# Amit M. Oza

Source: https://onco.cc/people/amit-oza/  
OnCo record `amit-oza` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Amit Oza is a gynaecologic oncologist who led early olaparib and niraparib studies in ovarian cancer.

## Summary

Amit M. Oza is Head of the Division of Medical Oncology and Hematology and Director of the Cancer Clinical Research Unit at the Princess Margaret Cancer Centre. He is a gynaecologic oncologist known for leading early olaparib and niraparib studies that established PARP inhibition in BRCA-mutant and platinum-sensitive ovarian cancer. His selected paper reports a randomised phase 2 trial of olaparib combined with chemotherapy in recurrent platinum-sensitive ovarian cancer. He now heads medical oncology at Princess Margaret and continues to lead gynaecologic trials in ovarian and endometrial cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Head, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit
- Specialisms: Ovarian cancer; PARP inhibitors; Gynaecologic trials

## Sources

- UHN profile: https://www.uhnresearch.ca/researcher/amit-m-oza
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Oza%20AM%5BAuthor%5D

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Niraparib](https://onco.cc/drugs/niraparib/), [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [Princess Margaret Cancer Centre](https://onco.cc/institutions/princess-margaret/)
- key papers: [SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer](https://onco.cc/key-papers/paper-solo-1-nejm-2018/)

---
JSON: https://onco.cc/api/v1/entities/amit-oza.json